Cancer nanomedicine meets immunotherapy: opportunities and challenges

doi:10.1038/s41401-020-0448-9

	Cancer nanomedicine meets immunotherapy: opportunities and challenges
	Sun, Qingxue 2,3; Bai, Xiangyang 2,3; Sofias, Alexandros Marios 2,3; van der Meel, Roy 4,5; Ruiz-Hernandez, Eduardo 6; Storm, Gert 7,8; Hennink, Wim E.7; De Geest, Bruno 9; Kiessling, Fabian 2,3,10; Yu, Hai-jun 1,11
刊名	ACTA PHARMACOLOGICA SINICA
	2020-07-01
卷号	41 期号:7 页码:954-958
关键词	nanomedicine immunotherapy targeting combination therapy clinical translation
ISSN号	1671-4083
DOI	10.1038/s41401-020-0448-9
通讯作者	Lammers, Twan(tlammers@ukaachen.de) ; Shi, Yang(yshi@ukaachen.de)
英文摘要	Cancer nanomedicines have shown promise in combination immunotherapy, thus far mostly preclinically but also already in clinical trials. Combining nanomedicines with immunotherapy aims to reinforce the cancer-immunity cycle, via potentiating key steps in the immune reaction cascade, namely antigen release, antigen processing, antigen presentation, and immune cell-mediated killing. Combination nano-immunotherapy can be realized via three targeting strategies, i.e., by targeting cancer cells, targeting the tumor immune microenvironment, and targeting the peripheral immune system. The clinical potential of nano-immunotherapy has recently been demonstrated in a phase III trial in which nano-albumin paclitaxel (Abraxane (R)) was combined with atezolizumab (Tecentriq (R)) for the treatment of patients suffering from advanced triple-negative breast cancer. In the present paper, besides strategies and initial (pre)clinical success stories, we also discuss several key challenges in nano-immunotherapy. Taken together, nanomedicines combined with immunotherapy are gaining significant attention, and it is anticipated that they will play an increasingly important role in clinical cancer therapy.
资助项目	European Research Council[864121] ; European Research Council[813086] ; European Research Council[817938] ; China Scholarship Council ; European Union (European Fund for Regional Development)[EFRE-0801767] ; German Research Foundation[DFG: GRK/RTG 2375] ; German Research Foundation[331065168] ; German Research Foundation[SFB 1066] ; Aachen Interdisciplinary Center for Clinical Research (IZKF)[O3-2] ; Federal Ministry of Education and Research (BMBF) ; Netherlands Research Council (NOW: ZonMW Vici grant)[016.176.622] ; National Natural Science Foundation of China[51873228] ; Lander[OPSF580] ; Ministry of Culture and Science of the German State of North Rhine-Westphalia (MKW) under the Excellence Strategy of the Federal Government
WOS关键词	IMMUNOGENIC CELL-DEATH ; T-CELLS ; NANOPARTICLES ; MICROENVIRONMENT ; DELIVERY ; SYSTEMS
WOS研究方向	Chemistry ; Pharmacology & Pharmacy
语种	英语
出版者	NATURE PUBLISHING GROUP
WOS记录号	WOS:000540983600002
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/291696]
专题	中国科学院上海药物研究所
通讯作者	Lammers, Twan; Shi, Yang
作者单位	1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China 2.Rhein Westfal TH Aachen, Inst Expt Mol Imaging, Uniklin RWTH Aachen, Aachen, Germany 3.Rhein Westfal TH Aachen, Helmholtz Inst Biomed Engn, Fac Med, Aachen, Germany 4.Eindhoven Univ Technol, Dept Biomed Engn, Lab Chem Biol, Eindhoven, Netherlands 5.Eindhoven Univ Technol, Inst Complex Mol Syst, Eindhoven, Netherlands 6.Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin, Ireland 7.Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, Utrecht, Netherlands 8.Univ Twente, MIRA Inst Biomed Technol & Tech Med, Dept Targeted Therapeut, Enschede, Netherlands 9.Univ Ghent, Dept Pharmaceut, Ghent, Belgium 10.Inst Med Image Comp, Fraunhofer MEVIS, Aachen, Germany
推荐引用方式 GB/T 7714	Sun, Qingxue,Bai, Xiangyang,Sofias, Alexandros Marios,et al. Cancer nanomedicine meets immunotherapy: opportunities and challenges[J]. ACTA PHARMACOLOGICA SINICA,2020,41(7):954-958.
APA	Sun, Qingxue.,Bai, Xiangyang.,Sofias, Alexandros Marios.,van der Meel, Roy.,Ruiz-Hernandez, Eduardo.,...&Shi, Yang.(2020).Cancer nanomedicine meets immunotherapy: opportunities and challenges.ACTA PHARMACOLOGICA SINICA,41(7),954-958.
MLA	Sun, Qingxue,et al."Cancer nanomedicine meets immunotherapy: opportunities and challenges".ACTA PHARMACOLOGICA SINICA 41.7(2020):954-958.